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Abstract
Whole genome sequencing of human tumours has revealed distinct patterns of mutation that 
hint at the causative origins of cancer. Experimental investigations of the mutations and mutation 
spectra induced by environmental mutagens have traditionally focused on single genes. With the 
advent of faster cheaper sequencing platforms, it is now possible to assess mutation spectra in 
experimental models across the whole genome. As a proof of principle, we have examined the 
whole genome mutation profiles of mouse embryo fibroblasts immortalised following exposure to 
benzo[a]pyrene (BaP), ultraviolet light (UV) and aristolochic acid (AA). The results reveal that each 
mutagen induces a characteristic mutation signature: predominantly G→T mutations for BaP, C→T 
and CC→TT for UV and A→T for AA. The data are not only consistent with existing knowledge but 
also provide additional information at higher levels of genomic organisation. The approach holds 
promise for identifying agents responsible for mutations in human tumours and for shedding light 
on the aetiology of human cancer.
Introduction
Mutagenesis drives the transformation of a normal cell to a tumour. 
A cancer genome is a historical record of mutagenic processes that 
have occurred throughout the life of a cancer patient, including 
mutations accrued during the normal part of the cell lineage as well 
as after neoplastic transformation (1–3). These mutations may result 
from endogenous mutagenic processes (e.g. spontaneous deamina-
tion of 5-methylcytosine) or exposure to exogenous mutagens, such 
as environmental chemicals or radiation. Additionally, mutations 
may develop due to failure of DNA repair pathways. A small num-
ber of mutations in a cancer cell (<10) are thought to confer a selec-
tive growth advantage (e.g. in TP53 or other cancer genes) and are 
referred to as driver mutations (3). The vast majority of mutations 
in a cancer are simply bystander events, passenger mutations that 
report exclusively on the biological mutational processes that have 
occurred throughout cancer development (1–3). Each mutational 
process leaves its own characteristic mark or mutational signature 
on the cancer genome, defined by the mechanisms of DNA damage 
and DNA repair that constitute it (2,3).
A variety of experimental systems have been used to study 
the endogenous and exogenous factors driving mutagenesis. 
Traditionally, experimental mutagenesis studies have been limited 
to the analysis of mutations in a single gene (e.g., HPRT, lacZ, cII, 
TP53) which were identified in tumours or by specifically selecting 
for the growth of mutated cells or clones from mutagen-treated cell 
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populations. Because each tumour or cell clone harboured only one 
or two mutations in a particular gene, patterns of mutations were 
inferred through pooling data collected from many samples, some-
times from different experiments.
The gene that is most commonly mutated in human cancers is the 
tumour suppressor gene TP53 (4). Nearly 30 000 TP53 mutations 
identified in human tumours have been catalogued in the IARC TP53 
mutation database (current version R17, http://p53.iarc.fr) and this 
resource has been valuable for identifying correlations between 
specific mutation signatures in human cancers and exposure to 
environmental mutagens [e.g. C>T and CC>TT mutations in squa-
mous carcinomas of the head and neck, associated with ultraviolet 
(UV)-radiation exposure; G>T mutations in smokers’ lung cancer, 
associated with exposure to polycyclic aromatic hydrocarbons such 
as benzo[a]pyrene (BaP); A>T mutations in urothelial carcinomas, 
associated with exposure to aristolochic acid I (AAI)] (5). Some of 
these signatures have been recapitulated experimentally using cells 
from the partial human TP53 knock-in (Hupki) mouse, in which 
exons 4–9 of human TP53 replace the corresponding mouse exons 
(6,7). Immortalised clones derived from carcinogen-exposed primary 
Hupki mouse embryo fibroblasts (MEFs) harbour patterns of TP53 
mutation that closely resemble those identified in human tumours 
from patients exposed to the same carcinogens (8–11).
Although valuable insights have been gleaned from the study of 
single gene mutagenesis, such analyses cannot possibly illuminate all 
of the complex influences operating in the genomes of cancer cells. 
Not all human tumours have mutations in TP53 and, of those that 
do, the mutation may be an early or late event in the pathogenesis 
of the tumour. Furthermore, a particular cancer sample usually has 
only one TP53 mutation, thus mutational spectra must be obtained 
by aggregating mutations from many tumours, usually of the same 
type. This can be effective in reporting the signature of an exposure 
if there is a single dominant exposure in that cancer type, for exam-
ple UV light in skin cancers or tobacco carcinogens in lung cancers. 
However, if multiple mutational processes have been operative in a 
particular cancer type, their signatures will become convoluted in 
the compiled TP53 mutational spectrum. The observed TP53 signa-
tures may also be influenced by selection for particular driver muta-
tions. Finally, it remains the case that signatures from only a small 
number of environmental carcinogens have been identified in human 
tumours from analysis of their TP53 mutation patterns.
Massively parallel next-generation sequencing (NGS) technology 
(12) has resulted in an extraordinary increase in the speed and scale 
of sequencing, permitting the exploration of all protein-coding exons 
(exome sequencing) or whole genomes (whole-genome sequencing, 
WGS) in samples from patients or experimental model systems 
(13,14). This technology enables the detection of hundreds or even 
thousands of mutations in a single sample, increasing the power 
of each experiment considerably. Furthermore, the distribution of 
mutations throughout the genome can now be explored to gain fur-
ther insights into mutagenic mechanisms. The complex biological 
insights buried within these large, multi-dimensional datasets can be 
dissected using mathematical separation approaches such as non-
negative matrix factorisation (NNMF) (15). For example, NNMF 
has been used to extract at least 21 distinct mutation signatures from 
WGS data across 30 different cancer types (1) including a few sig-
natures associated with exposure to carcinogens, such as tobacco 
smoke in lung cancer and UV radiation in malignant melanoma (1). 
Many novel signatures have also been uncovered (1) and the race is 
on to understand their aetiology.
In order to determine whether mutation signatures of in vitro 
carcinogen exposure could be extracted from a mammalian genome, 
and to explore additional insights that could be gained using a WGS 
approach, we sequenced the genomes of immortalised Hupki MEF 
clones exposed to the carcinogens BaP, AAI or ultraviolet C (UVC). In 
addition to determining the pattern and transcriptional strand bias for 
mutations induced by each agent, we were able to extract mutational 
signatures using NNMF and examine the effect of replication timing 
on mutagenesis. This study provides a perspective on how to use the 
genome as a physiological read-out of environmental exposures.
Materials and methods
MEF cell line information
The cell lines assessed here were derived in previous studies from 
primary Hupki MEF cultures exposed to the environmental carcino-
gens BaP, UV or AAI, as well as unexposed cultures (Supplementary 
Table  1). Briefly, primary MEFs were isolated from Day 13.5 
Trp53tm/Holl mouse embryos which contain the Hupki gene, exposed 
to BaP (1 µM, 6  days), AAI (50 µM, 4  days), UVC (20 J/m2), or 
left untreated, and then subjected to serial passaging according to a 
modified 3T3 protocol (16,17). Immortal clones that emerged from 
senescent cultures were passaged at low density for several passages 
to establish cell lines. The lines chosen for this study each harboured 
an inactivating TP53 mutation (Supplementary Table 1). Genomic 
DNA was isolated from the cells by a standard phenol/chloroform 
extraction method and stored at −20°C.
Massively parallel sequencing and alignment
Short insert 500 bp genomic libraries were constructed, flowcells 
prepared and sequencing clusters generated according to Illumina 
library protocols (18). 100 base paired-end sequencing was per-
formed on Hiseq 2000 genome analyzers in accordance with the 
Illumina Genome Analyzer operating manual. Short insert paired-
end reads were aligned to the reference mouse genome (NCBIM37) 
using Burrows-Wheeler Aligner, BWA (v0.5.9) (19).
Processing of genomic data
Mutation-calling: substitutions
A bespoke algorithm, CaVEMan (Cancer Variants Through 
Expectation Maximisation: http://cancerit.github.io/CaVEMan/) 
was used for calling somatic substitutions in MEFs. CaVEMan uti-
lises an expectation-maximisation (EM) algorithm to call variants in 
second-generation sequencing reads. Given the reference base and 
copy number status, CaVEMan generates a probability score for 
potential genotypes at each genomic position. A high specificity was 
essential for the purposes of downstream analyses. As such, further 
postprocessing filters of potential somatic genotypes were designed 
to eliminate false positive calls arising from: genomic features that 
generate mapping errors, for example regions of excessively high 
coverage due to collapsed repeat sequences in the reference genome 
(http://genome.ucsc.edu/), systematic sequencing artifacts, for exam-
ple motifs known to cause errors of phasing during the sequencing 
reaction or sequencing artifacts arising in at least 5% of reads in 
at least 2 samples from a panel of unrelated samples, misalignment 
caused by germline insertions/deletions and germline SNPs.
Mutation-calling: insertions/deletions
Insertions and deletions in the immortalised and primary MEF 
genomes were called using a modified Pindel version 2.0. on the 
mouse NCBIM37 genome build (20). Variants were screened against 
a panel of unrelated samples. Indels were further filtered against pos-
sible germline SNPs (dbSNP).
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Mutation-calling: structural variation
Structural variants were first discovered using a bespoke algorithm, 
BRASS (BReakpoint AnalySiS) (https://github.com/cancerit/BRASS) 
through discordantly mapping paired-end reads from short insert 
data by using BWA alignments. Next, discordantly mapping read 
pairs that were likely to span breakpoints, as well as a selection 
of nearby properly paired reads, were grouped for each region of 
interest. Using the Velvet de novo assembler (21), reads were locally 
assembled within each of these regions to produce a contiguous con-
sensus sequence of each region.
Transcriptional strand characterisation
The nucleotide sequence of the primary mRNA transcript is iden-
tical to the sense/non-template/non-transcribed strand except that 
U replaces T, and is complementary to that of the anti-sense/tem-
plate/transcribed strand. All mutations were called on the + strand 
of the reference genome, were placed into the ‘pyrimidine’ context 
and noted if so. Transcriptional strand was assigned for each pyrim-
idine-based mutation. Assignment of transcriptional strands was 
performed by considering only protein coding genes. Of the total of 
22 556 protein coding genes, 11 209 (513 086 613 bp) were on the + 
strand and 11 347 (494 818 895 bp) were on the − strand.
Replication domain characterisation
Reference coordinates for replication landmarks were inferred from 
Repli-seq data obtained from the ENCODE project (22) (https://
www.encodeproject.org/) for MEFs. In Repli-Seq experiments, cell 
lines are first isolated into cell cycle fractions of newly replicated 
DNA and each fraction is sequenced. To visualise genome-wide rep-
lication patterns as a continuous function, percentage-normalisation 
of sequencing tags was followed by a wavelet-smoothed transforma-
tion. The resolution of these data is relatively limited when com-
pared to the data obtained from Repli-Seq experiments performed 
in humans. Original data contained 384 796 probes (average size of 
61 bp) encompassing 234 727 739 bp of the mouse reference genome. 
ENCODE blacklist for mm9 genome (22) was used to exclude 
regions showing an artificially high signal. This filtering process 
removed 280 probes, and a final list of 384 516 probes encompass-
ing 23 455 659 bp of the mouse reference was obtained.
Replication time domains
For analyses requiring conservative distinctions between early and 
late replication time domains, an EM algorithm for multivariate nor-
mal mixtures was applied. The model was based on the assumption 
that the observed Repli-seq signal was a random sample from a finite 
normal mixture of three distributions (corresponding to early, late 
and unknown domains) (Supplementary Figure 1A), where each dis-
tribution can be completely described by its mean μi and variance σi
2
. Standard EM algorithm for normal mixtures was used to estimate 
the parameters μi and variance σi
2 associated with the three normal 
distributions fitting the Repli-seq data. The intersections between 
the fitted normal distributions were used to classify the domains. 
Adjacent probes belonging to the same replication time domain 
were merged to obtain larger regions. The final list contained 1270 
early replicated regions (average size of 523 813.8 bp for a total 
of 676 673 544 bp) and 1458 late replicated regions (average size 
of 772 977.4 bp for a total of 1 127 001 075 bp). All analyses were 
corrected for genomic size of the relevant regions. AT/GC content 
(Supplementary Figure 1B) and distribution of protein-coding genes 
(Supplementary Figure  1C) are in-keeping with expectations for 
early and late replication domains.
Characterisation of replication strands
Replication origins do not fire as a part of a clear, deterministic 
program, instead occurring individually and as clusters (23–25). 
Replication strands were defined using Repli-seq signals: peaks (local 
maxima) in the smoothened profile correspond to replication initia-
tion zones while valleys (local minima) correspond to replication ter-
mination zones (22). Finite difference approximations of second and 
first derivatives were used to identify Repli-seq signal local maxima 
[f″(x) < 0] and local minima [f″(x) > 0] corresponding to potential 
origin firing sites, and to distinguish between leading [f′(x) < 0] and 
lagging [f′(x) >  0] strand, respectively. Derivative functions were 
defined in agreement with p and q arm chromosome orientation. 
We named the replication strand as p2q-leading and p2q-lagging. As 
for replication time domains, adjacent probes belonging to the same 
replication strand were merged to obtain larger regions. In order to 
remain conservative in downstream assignments (26,27), we only 
considered merged regions containing at least three probes, discard-
ing ambiguous regions that were <10 kb in length. The final list con-
tained 11 568 p2q-leading regions (average size of 103 452.6 bp for 
a total of 1 196 739 303 bp) and 11 579 p2q-lagging regions (aver-
age size of 101,406.1 bp for a total of 1 174 180 686 bp). Derived 
p2q-leading and p2q-lagging strands are comparable in genomic 
footprint and AT/CG content (Supplementary Figure 1D). However, 
there were no differences observed in the distribution of mutations 
between leading and lagging strands, respectively.
Results
Whole genome mutation spectra and strand bias in 
carcinogen-exposed MEFs
Following WGS we identified 14 929, 25 100 and 20 111 mutations, 
respectively, in each treated subclone (BaP, AAI and UV). In addition, 
4913 mutations were identified in the untreated subclone. Exploring 
the totality of mutations in these cell lines (Figure 1), striking visually 
discernible differences can be appreciated by the substitution muta-
tional spectra while also demonstrating a lack of a specific pheno-
type in the indels and rearrangements in these otherwise structurally 
quiescent genomes.
The mutation spectra identified in these subclones were typical 
of those previously reported to be associated with each of the expo-
sures. Hupki MEFs treated with BaP had substantial numbers of 
C>A (substitutions are referred to by the pyrimidine of the mutated 
Watson-Crick base pair) transversions, characteristic of bulky DNA 
adducts formed at guanine residues by the major reactive metabolite 
of BaP, benzo[a]pyrene-7,8-diol-9,10-epoxide. AAI-treated MEFs 
showed a majority of T>A transversions, a mutational pattern char-
acteristic of bulky adducts formed at adenine residues by reactive 
aristolactam nitrenium ions following AAI metabolism. C>T tran-
sition mutations were the most common type of mutation seen in 
MEFs treated with UV radiation and a significant proportion of 
these were highly distinctive CC>TT double substitutions, typical of 
mutagenesis associated with pyrimidine dimers caused by UV expo-
sure. Intriguingly, untreated MEFs carried largely T>G transversions.
We found that a transcriptional strand bias was detectable in cells 
treated with AAI or BaP, with a significant excess of mutations found 
on the non-transcribed strand for A>T transversions in the AAI-
treated MEFs and for G>T transversions in the BaP-treated MEFs 
(Figure 2A). This is in keeping with the activity of transcription-cou-
pled nucleotide excision repair (TC-NER) on the transcribed strand, 
a branch of NER that removes RNA polymerase II-blocking DNA 
lesions caused by each of these mutagens. Mutations in MEFs treated 
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Figure 1. Whole-genome sequenced read-outs of four different Hupki MEF clones exposed to different mutagens demonstrate distinctive differences between 
clones. (A) from a clone of untreated cells, containing 4913 mutations; (B) from a clone of BaP-treated cells, containing 14 929 mutations; (C) from a clone 
of AAI-treated cells, containing 25 100 mutations; (D) from a clone of UV-irradiated cells, containing 20 111 mutations. Features in Circos plots on left depict 
karyotypic ideogram outermost, then moving inwards: base substitutions, plotted as rainfall plots (log10 intermutation distance, dot colours: blue  =  C>A, 
black = C>G, red = C>T, grey = T>A, green = T>C, pink = T>G). Ring with short green lines =  insertions, ring with short red lines = deletions. Central line: 
grey = intrachromosomal rearrangements, pink = deletions, green = tandem duplications. Histograms in the centre show substitution types. Histograms on right 
show deletions and insertions (upper) and rearrangements (lower). The y-axis of each histogram indicates the number of mutations. Enlarged versions of the 
Circos plots can be viewed in Supplementary Figures 2–5.
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Figure  2. (A) Transcriptional strand bias of somatic base substitutions derived from Hupki MEFs exposed to various mutagens. Blue  =  C>A, black  =  C>G, 
red = C>T, grey = T>A, green = T>C and pink = T>G. P-value for significance calculated using a binomial proportions test. (B) Mutation signatures extracted 
from base substitutions in treated and untreated MEFs. (C) The proportion of mutations attributed to human cancer signatures in each MEF cell line. Pearson 
correlation for similarity of MEF extracted signatures to those previously extracted from primary human cancers is provided. An enlarged version of B can be 
viewed in Supplementary Figure 6.
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with UV, however, did not exhibit a transcriptional strand bias. This 
is in contrast to what has been observed in UV-associated human 
tumours, where C>T mutations are biased to the non-transcribed 
strand (1). The reason for this difference is unclear, but perhaps the 
repair of UVC-induced DNA damage in MEFs is different to that of 
sunlight-induced (i.e. UVA/UVB) DNA damage in human cells.
Mutation signatures extracted using NNMF
The mathematical method NNMF allows extraction of complex 
mutation signatures of 96 elements (six base substitution classes with 
four 5′ and four 3′ flanking base options). This algorithm and its 
application is described in detail by Alexandrov et al. (15) Performing 
NNMF on the WGS profiles from the untreated and mutagen-treated 
cell lines, we found four distinct mutation signatures (Figure  2B). 
Three were unique to individually treated MEFs and corresponded 
to known environmental exposures (Figure 2C): the signature identi-
fied in MEFs treated with BaP (Extracted Signature C) was similar 
to Signature 4, which was extracted previously from smoking-asso-
ciated lung cancers; the signature identified in MEFs treated with 
UVC radiation (Extracted Signature D) was similar to Signature 7 
extracted from skin cancers associated with UV exposure; the sig-
nature identified in AAI-treated MEFs (Extracted Signature B) was 
nearly identical to Signature 22 extracted from urothelial cancers 
caused by exposure to the associated mutagen (http://cancer.sanger.
ac.uk/cosmic/signatures). Curiously, however, one signature was pre-
sent in all four MEF clones, including the cells that had not been 
exposed to a mutagen. This signature (Extracted Signature A) is 
identical to Signature 17 and has been identified primarily in stom-
ach and oesophageal cancers, hepatocellular carcinoma and lym-
phoma. This very distinctive signature has been reported in a variety 
of different cell types including in vitro mouse cell models (daughter 
subclones of organoids derived from murine gastrointestinal tract 
cells) (28). The cause of this signature, however, remains unknown.
NNMF also permits quantification of the amount of the differ-
ent signatures in each of the cell clones. We found that each of the 
signatures associated with specific carcinogen exposures was iden-
tified only in individually treated MEFs, apart from Signature 17, 
which was present in all four MEF lines whether treated or not. This 
implies that a background mutational process causing Signature 17 
was acting in all the MEF lines.
Relationship of mutation spectra to genomic 
architecture
WGS approaches permit the exploration of relationships between 
the patterns of mutagenesis and features of the genome. Exploiting 
resources such as ENCODE, the genome can be compartmental-
ised according to replication time and strands based on RepliSeq 
experiments previously performed on MEFs. Although we did not 
find any significant differences in the distribution of mutations 
between leading and lagging replicative strands for base substitu-
tions (data not shown), we observed intriguing differences in the dis-
tribution of mutations between early and late replication domains 
(Supplementary Figure  7). With the exception of C>T transitions 
in the UV-treated MEFs, the dominant mutation class for each of 
the treated MEFs (T>A in AAI-treated and C>A in BaP-treated) and 
untreated MEFs (T>G mutations) demonstrated a higher mutation 
density late in replication, regardless of whether they were within the 
gene footprints (transcribed vs. non-transcribed) or intergenic. The 
unusual behaviour of C>T mutations in the UVC-treated MEFs could 
be due to the fact that the cells were acutely exposed to UVC only 
once, whereas cells were exposed to BaP and AAI for several days 
and DNA damage would have occurred throughout several rounds 
of replication. It remains to be determined whether chronic exposure 
to UV light would alter the distribution of mutations compared with 
a single, acute treatment. These analyses provide first insights into 
how to capitalise on analyses of genome-wide mutagenesis.
Discussion
From this proof-of-principle study, several important principles 
emerge. WGS of MEFs treated with mutagens reveals patterns of 
mutation previously observed in single gene analyses (e.g. TP53) 
but with much larger numbers of mutations, allowing greater preci-
sion of characterisation of the mutational signature than could ever 
have been obtained from analysis of a single gene. Strikingly, this 
was achieved by sequencing only a single sample for each mutagen 
exposure. Even subtle differences in mutational signature, for exam-
ple between different components of tobacco smoke, may in future 
be detectable given these amounts of data. Transcriptional strand 
bias and the impact of many other features of the genome landscape 
upon mutagenesis are extractable with the statistical power available 
from such studies. Other studies coming to similar conclusions using 
exome sequencing have recently been published (29–31). However, 
the extraordinary number of mutations and the much greater vari-
ation in genome landscape features visible from a whole genome 
sequence will undoubtedly provide great additional richness of 
insight.
In vitro model systems (e.g. cell-based) provide a means for 
studying patterns of mutagenesis under controlled conditions, 
now at the level of the genome. This can provide a detailed muta-
tion signature to connect with a specific mutagenic exposure that 
far exceeds current understanding. To reduce costs associated with 
sequencing or to increase experimental power, model organisms 
with smaller genomes such as Saccharomyces cerevisiae (12 Mbp), 
S. pombe (12.57 Mbp) and Caenorhabditis elegans (100 Mb) may, 
in some instances, be tractable systems to sequence compared with 
the mouse (2.5 Gb) or human genome (3.2 Gb). Multiple clones can 
be sequenced at a relatively modest cost. As a comparison, using 
current sequencing techniques, one lane of a HiSeq 2000 Illumina 
sequencing run provides ~10-fold coverage of a human genome or 
an equivalent sequence coverage of 100 yeast clones. Recently, Meier 
et al. (32) examined whole genome mutation signatures in C. elegans 
exposed to the mycotoxin aflatoxin B1 and two chemotherapeutic 
agents, cisplatin and mechlorethamine. Mutation profiles induced by 
these carcinogens reflected the known biochemistry of each agent 
and resembled signatures observed in human cancers and develop-
mental genomic disorders, thus indicating that such an approach 
could be applied for additional carcinogens. However, differences in 
genome composition, genome architecture, cellular physiology and 
DNA repair pathways exist between species and the generalisability 
of sequencing approaches from model organism to humans may be 
limited. Furthermore, smaller (non-human) genomes are smaller tar-
gets for mutation, such that many more genomes (and hence many 
more libraries for sequencing) may be required to obtain the same 
amount of information that is obtainable from larger (human or 
mouse) genomes, eliminating any potential cost reductions.
As we attempt to identify the possible environmental origins of 
mutation signatures observed in human tumours, it would be use-
ful to have a curated dataset of signatures extracted from human 
cells exposed to specific mutagens under controlled conditions. The 
advent of newer, faster genome sequencing technologies means that 
we can move towards this goal, whereby mutations can be examined 
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across the exome or the whole genome, with or without a selec-
tion procedure. Key to the successful documentation of such data 
is a well-constructed experiment. Here, a proposition would be to 
use normal human cells as a reference parental line, such as human 
induced pluripotent stem cells, which are indefinitely proliferative 
and easily subcloned. Cells could be treated with mutagens suspected 
of causing cancer in humans, and daughter subclones, preferably 
isolated and expanded without any phenotypic selection processes, 
could be derived and used for identifying genome-wide mutational 
signatures. Ideally such cells should have the capacity to metaboli-
cally activate mutagens, but, if not, exogenous metabolising systems 
(e.g. S9 mix) could be incorporated into the mutagen-treatment 
protocol. In theory, each daughter cell line should carry the signa-
ture associated with the specific mutagen exposure. Background 
mutagenesis associated with culture or other shared exposures will 
be detectable and quantifiable (and therefore easily subtracted). 
These curated signatures of known cause could then be included in 
a reference database, which could then be compared with signatures 
extracted from human cancers, normal human cells or other sources 
to look for similarities that might provide clues to cancer aetiology.
Based on analyses of single gene mutation spectra, only a hand-
ful of carcinogens have yet been shown to induce unique mutational 
fingerprints, whereas many agents generate overlapping spectra (33). 
It is axiomatic that a wealth of additional information will emerge 
from widening the scope of analysis from a single gene to the whole 
genome, whereby WGS will likely reveal more complex spectra that 
are unique to individual mutagens. Further, carcinogen-induced 
mutation signatures can be expanded to include a wider sequence 
context, dinucleotide base substitutions and insertions/deletions. 
This approach will be highly useful in elucidating the endogenous 
and exogenous origins of mutations in human cells and in identifying 
the causative agents of human cancers. With many cancers suspected 
of being influenced by as-yet-unidentified environmental causes, the 
tracking down of these causes will be a crucial step towards achiev-
ing the ultimate public health goal of cancer prevention.
Supplementary data
Supplementary Table 1 and Figures 1–7 are available at Mutagenesis 
Online.
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